Last month, the European Federation of Associations of Health Product Manufacturers (EHPM) claimed the meeting "lacked substance" and failed to address its main objection: insufficient differentiation between assessments for types of claim, under Articles 13.5/14 and 13.1 claims.
Catherine Geslain-Lanéelle, EHPM's executive director, said EFSA had adopted 63 scientific opinions related to children's development and disease risk reduction claims (Article 14) and 22 opinions related to health claims applications based on newly developed science and/or proprietary data (Article 13.5).
Of more than 4,600 general function (Article 13.1) health claims submitted via the Member States and the European Commission, EFSA had evaluated over 930 and adopted 125 opinions.
The next opinion from EFSA's Scientific Panel on Dietetic Products, Nutrition & Allergies will be published in September.